
    
      Design A randomized, single-blind, parallel-group, controlled clinical trial. Setting
      Diabetes clinic of a teaching hospital in Shenzhen China Participants A total of 30
      participants with type 1 diabetes, aged 18-60 years, will be recruited and randomly assigned
      to receive either probiotics (n = 15) or placebo (n = 15) for 12 weeks.

      Outcomes Primary outcomes were glycemic control related parameters, and secondary outcomes
      were anthropomorphic variables, lipid profile, blood pressure and high-sensitivity C-reactive
      protein. The gut microbiota profile will be analyzed before and after intervention and
      between groups.
    
  